Previous 10 | Next 10 |
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-05-07 12:50:20 ET Summary Despite NPDR primary endpoint miss, potential exists with EyePoint Pharmaceuticals releasing 12-month phase 2 PAVIA data; potential for continued advancement depending upon data. LUGANO and LUCIA are two pivotal phase 3 studies expected to be initiat...
A look at the top 10 most actives in the United States Palantir Technologies Inc. Class A (PLTR) rose 8.1% to $25.21 on volume of 141,121,870 shares Lyra Therapeutics Inc. (LYRA) fell 87.1% to $0.5215 on volume of 107,579,343 shares PROSHARES TRUST (SQQQ) fell 3.4% to $10.7 on volume of 9...
2024-05-06 14:21:52 ET Summary EyePoint Pharmaceuticals, Inc. stock surged following positive Phase 2 trial outcomes in wet AMD, showing non-inferiority to Eylea. Despite success in wet AMD, 1901 showed disappointing results in an NPDR trial, failing its primary endpoint. Fina...
2024-05-06 13:17:53 ET More on Mid-day movers & stocks. Manitex International, Inc. 2024 Q1 - Results - Earnings Call Presentation Manitex International, Inc. (MNTX) Q1 2024 Earnings Call Transcript Manitex International, Inc. (MNTX) Q4 2023 Earnings Call Transcr...
2024-05-06 10:01:41 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
A look at the top 10 most actives in the United States XBP Europe Holdings Inc. (XBP) rose 69.1% to $3.5846 on volume of 37,660,870 shares Lyra Therapeutics Inc. (LYRA) fell 90.2% to $0.3942 on volume of 21,985,500 shares NIO Inc. American depositary shares each representing one Class A (...
2024-05-06 09:24:05 ET EyePoint Pharmaceuticals ( NASDAQ: EYPT ) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase 2 study for its eye drug Duravyu, also known as EYP-1901, failed to meet its primary endpoint in the treatment of non-proliferative di...
2024-05-06 08:26:44 ET More on pre-market losers & stocks. GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come Predictive Oncology Inc. (POAI) Q4 2023 Earnings Call Transcript ...
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no drug-related serious adverse events – ...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...